NeuroScientific Biopharmaceuticals clears key US Crohn’s trial hurdle
NeuroScientific Biopharmaceuticals has landed key US backing for its Phase 2 stem cell Crohn’s trial, green-lighting a planned year-end start subject to final preparations.
NSB
Pharmaceuticals, Biotechnology & Life Sciences
Neuroscientific Biopharmaceuticals
- Short interest
- 0.00%
- −0.01 pp 30d
- as of 3 July 2026
- Reported shorts
- 3.8K
- Shares on issue
- 389.719M
Neuroscientific Biopharmaceuticals (NSB) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASXUS FDA Provides Positive Feedback on Planned Phase 2 Trial
other announcement
Google NewsNeuroScientific Biopharmaceuticals (ASX:NSB) Rises 5% as StemSmart Program Progresses - Kalkine
NeuroScientific Biopharmaceuticals (ASX:NSB) Rises 5% as StemSmart Program Progresses Kalkine
NeuroScientific specialist hire sets stage for major Crohn’s trial
NeuroScientific Biopharmaceuticals has hired Southern Star Research for a phase two trial of its StemSmart Crohn’s disease therapy in Australia and the US.
Leading CRO Appointed for Phase 2 Crohn's Trial
other announcement
Notice of Annual General Meeting & Proxy Form
other announcement
Letter to Shareholders & Proxy Form
other announcement
Resignation and Appointment of Auditor
other announcement
NeuroScientific locks in key US FDA meeting
NeuroScientific has locked in a key meeting with the US FDA for its StemSmart technology aimed at treating refractory Crohn’s disease in a planned Phase 2 trial.
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Is NeuroScientific Biopharmaceuticals (ASX: NSB) Still Worth Watching After Today's Drop? - Kalkine
Is NeuroScientific Biopharmaceuticals (ASX: NSB) Still Worth Watching After Today's Drop? Kalkine
Change of Director's Interest Notice x2
director_dealing announcement
Daily Special: ClearVue Technologies, NeuroScientific Biopharmaceuticals, Lithium Energy - Sharecafe
Daily Special: ClearVue Technologies, NeuroScientific Biopharmaceuticals, Lithium Energy Sharecafe
Small Caps
NeuroScientific hails 80% clinical response in Crohn’s stem cell program
NeuroScientific Biopharmaceuticals has reported an 80% response rate from five Crohn’s disease patients treated with its StemSmart cell therapy, with all patients showing improvement.
Why NeuroScientific Biopharmaceuticals (ASX:NSB) Shares are Trading Higher on Tuesday? - Kalkine
Why NeuroScientific Biopharmaceuticals (ASX:NSB) Shares are Trading Higher on Tuesday? Kalkine
NeuroScientific (ASX:NSB) hits 80% Crohn's response and pulls forward Australian approval - Stocks Down Under
NeuroScientific (ASX:NSB) hits 80% Crohn's response and pulls forward Australian approval Stocks Down Under
Remarkable Results from Patients treated with StemSmart
other announcement
StemSmart Manufacturing Scale-Up Transfer Advances
other announcement
Successful Clinical Results Achieved under Special Access
other announcement
Date of AGM & Closing Date for Director Nominations
other announcement
Previous StemSmart Studies Support Renal Transplantation
other announcement
Presentation - TechKnow Invest Roadshow Conference
other announcement
NeuroScientific Partners with Leading Biologic Manufacturer
other announcement
Dr Catherine Cole Appointed as Chief Medical Officer
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement